$KALV +114% on public offering

$KALV is a pharmaceuticals company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company’s product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors.

Here is the link of the press release.

 

Here is the graph of the day.

 

 

Here is the 30 day overview.

You May Also Like

$AHPI+128%

PBTS + 100%

$MRIN .. AGAIN +130%

$CERE+136%

Leave a Reply

Your email address will not be published. Required fields are marked *

EMAIL SIGNUP